JBIO
Price:
$14.38
Market Cap:
$469.16M
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Industry
Biotechnology
IPO Date
2025-04-29
Stock Exchange
NASDAQ
Ticker
JBIO
According to Jade Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.51. This represents a change of 6.96% compared to the average of -4.22 of the last 4 quarters.
The mean historical PE Ratio of Jade Biosciences, Inc. over the last ten years is -16.20. The current -4.51 PE Ratio has changed 2.68% with respect to the historical average. Over the past ten years (40 quarters), JBIO's PE Ratio was at its highest in in the June 2024 quarter at -0.49. The PE Ratio was at its lowest in in the March 2024 quarter at -9.22.
Average
-16.20
Median
-10.21
Minimum
-57.98
Maximum
-1.09
Discovering the peaks and valleys of Jade Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 249.12%
Maximum Annual PE Ratio = -1.09
Minimum Annual Increase = -86.21%
Minimum Annual PE Ratio = -57.98
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -3.80 | 249.12% |
| 2024 | -1.09 | -86.21% |
| 2023 | -7.89 | -43.32% |
| 2022 | -13.92 | 11.07% |
| 2021 | -12.53 | -78.39% |
The current PE Ratio of Jade Biosciences, Inc. (JBIO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.26
5-year avg
-7.85
10-year avg
-16.20
Jade Biosciences, Inc.’s PE Ratio is less than Silence Therapeutics plc (-4.05), less than Lyell Immunopharma, Inc. (-1.33), greater than Aldeyra Therapeutics, Inc. (-7.76), less than Kyverna Therapeutics, Inc. (-2.47), greater than Contineum Therapeutics, Inc. Class A Common Stock (-6.68), less than Genelux Corporation (-3.19), less than XOMA Royalty Corp. (16.71), greater than Tectonic Therapeutic, Inc. (-8.14), less than AC Immune S.A. (-3.65),
| Company | PE Ratio | Market cap |
|---|---|---|
| -4.05 | $358.59M | |
| -1.33 | $452.07M | |
| -7.76 | $262.70M | |
| -2.47 | $400.69M | |
| -6.68 | $474.52M | |
| -3.19 | $100.81M | |
| 16.71 | $329.70M | |
| -8.14 | $618.31M | |
| -3.65 | $323.93M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Jade Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Jade Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Jade Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Jade Biosciences, Inc. (JBIO)?
What is the highest PE Ratio for Jade Biosciences, Inc. (JBIO)?
What is the 3-year average PE Ratio for Jade Biosciences, Inc. (JBIO)?
What is the 5-year average PE Ratio for Jade Biosciences, Inc. (JBIO)?
How does the current PE Ratio for Jade Biosciences, Inc. (JBIO) compare to its historical average?